ProGenTech Raises $21 million

East meets West as ProGenTech, a research tools company based in China and the US, attracts new investors Bay City Capital and DT Capital.

In 2007, five Chinese health care companies, including WuXi PharmaTech Inc. and China Nepstar Drug Stores, went public on US Exchanges, raising nearly a billion dollars. That impressive performance has triggered a flood of interest among Western-based venture capitalists and hedge fund managers. To date, China-based contract research organizations have attracted the lion’s share of foreign investment, but recently other start-ups, including those with East/ West business models, are starting to command attention. (See "China: The Asian Dragon Lures Foreign Investors," START-UP, February 2008 Also see "China: The Asian Dragon Lures Foreign Investors" - Scrip, 1 February, 2008. and "China: The Wild, Wild East for Medical Devices," this issue Also see "China: The Wild, Wild East for Medical Devices" - Medtech Insight, 1 May, 2008..)GenturaDx is just the latest company to capitalize on the China buzz. In early April, the company announced its first round of institutional investing: a $21 million Series C led by Bay City Capital and DT Capital. [See Deal]

According to Fred Craves, managing partner at Bay City, the firm had been looking at investment opportunities in China for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

Burden Is Too Heavy For Medtechs To Go It Alone On Complex Medtech AI Projects

 

Medtech companies require expertise to navigate complex AI regulations and integrate AI in medical software while addressing regulatory challenges, claims expert AI consultant with medtech experience.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

 

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

More from Geography

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

 

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Commission Decision Launches Pediatric And Rare Disease Expert Group

 

A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.